

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number		10722374
	Filing Date		2003-11-25
	First Named Inventor	David Bebbington	
	Art Unit	1624	
	Examiner Name	Venkataraman Balasubramanian	
	Attorney Docket Number	VPI/00-130-08 CON US	

U.S. PATENTS						<a href="#">Remove</a>
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	6558657	B1	2003-05-06	Mandeville, III et al.	
	2	6495582	B1	2002-12-17	Hale et al.	
	3	6526509	B1	2003-03-04	Hale et al.	
	4	5710158		1998-01-20	Myers et al.	
	5	5916906		1999-06-29	Giese et al.	
	6	6200977	B1	2001-03-13	Cushing et al.	
	7	6528513	B2	2004-03-04	Cushing et al.	
	8	6743791	B2	2004-06-01	Vertex Pharmaceuticals Incorporated	

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10722374
Filing Date	2003-11-25
First Named Inventor	David Bebbington
Art Unit	1624
Examiner Name	Venkataraman Balasubramanian
Attorney Docket Number	VPI/00-130-08 CON US

9	7253187	B2	2007-08-07	Vertex Pharmaceuticals Incorporated	
10	6949544	B2	2005-09-27	Vertex Pharmaceuticals Incorporated	
11	6642227	B2	2003-11-04	Vertex Pharmaceuticals Incorporated	
12	7084159	B2	2006-08-01	Vertex Pharmaceuticals Incorporated	
13	6838464	B2	2005-01-04	AstraZeneca AB	
14	6593326	B1	2003-07-15	AstraZeneca AB	
15	6727251	B2	2004-04-27	Vertex Pharmaceuticals Incorporated	

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

**U.S.PATENT APPLICATION PUBLICATIONS**

Remove

Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	20030078166	A1	2003-04-24	Davies et al.	
	2	20050004110	A1	2005-01-06	Bebbington et al.	

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10722374
Filing Date	2003-11-25
First Named Inventor	David Bebbington
Art Unit	1624
Examiner Name	Venkataraman Balasubramanian
Attorney Docket Number	VP/00-130-08 CON US

3	20030073687	A1	2003-04-17	Bebbington et al.	
4	20030064981	A1	2003-04-03	Knegtlef et al.	
5	20030055044	A1	2003-03-20	Davies et al.	
6	20030083327	A1	2003-05-01	Davies et al.	
7	20040097501	A1	2004-05-20	Bebbington et al.	
8	20030078275	A1	2003-04-24	Bebbington et al.	
9	20030055068	A1	2003-03-20	Bebbington et al.	
10	20030036543	A1	2003-02-20	Bebbington et al.	
11	20040002496	A1	2004-01-01	Bebbington et al.	
12	20030225073	A1	2003-12-04	Bebbington et al.	
13	20040009974	A1	2004-01-15	Bebbington et al.	

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10722374
Filing Date	2003-11-25
First Named Inventor	David Bebbington
Art Unit	1624
Examiner Name	Venkataraman Balasubramanian
Attorney Docket Number	VPI/00-130-08 CON US

14	20030199526	A1	2003-10-23	Choquette et al.	
15	20030092714	A1	2003-05-15	Cao et al.	
16	20040229875	A1	2004-11-18	Cao et al.	
17	20030096816	A1	2003-05-22	Cao et al.	
18	20040023963	A1	2004-02-05	Cao et al.	
19	20030207873	A1	2003-11-06	Harrington et al.	
20	20030096813	A1	2003-05-22	Cao et al.	
21	20030144309	A1	2003-07-31	Choon-Moon	
22	20040009996	A1	2004-01-15	Moon et al.	
23	20030171389	A1	2003-09-11	Bemis et al.	
24	20040029857	A1	2004-02-12	Hale et al.	

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10722374
Filing Date	2003-11-25
First Named Inventor	David Bebbington
Art Unit	1624
Examiner Name	Venkataraman Balasubramanian
Attorney Docket Number	VP1/00-130-08 CON US

25	20050234059	A1	2005-10-20	Hale et al.	
26	20040097531	A1	2004-05-20	Ledeboer et al.	
27	20030022885	A1	2003-01-30	Bebbington et al.	
28	20030004161	A1	2003-01-02	Bebbington et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button. [Add](#)

**FOREIGN PATENT DOCUMENTS**

[Remove](#)

Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> j	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1	0019811	EP	A1	1980-12-10	Ciba-Geigy AG		<input type="checkbox"/>
	2	2052487	GB	A	1981-01-28	Ciba-Geigy AG		<input type="checkbox"/>
	3	06-65237	JP	A	2007-10-25	Nissan Chem. Ind., Ltd.		<input checked="" type="checkbox"/>
	4	10-130150	JP	A	1998-05-19	Dainippon Pharmaceutical Co., Ltd.		<input checked="" type="checkbox"/>
	5	2458965	DE	A1	1976-06-16	Bayer AG		<input checked="" type="checkbox"/>

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10722374
Filing Date	2003-11-25
First Named Inventor	David Bebbington
Art Unit	1624
Examiner Name	Venkataraman Balasubramanian
Attorney Docket Number	VP/00-130-08 CON US

6	2000-026421	JP	A	2000-01-25	Kumiai Chem Ind Co. Ltd.	<input type="checkbox"/>
7	9918781	WO	A1	1999-04-22	Cytovia, Inc.	<input type="checkbox"/>
8	0125220	WO	A1	2001-04-12	Kinetix Pharmaceuticals Inc.	<input type="checkbox"/>
9	0208244	WO	A2	2002-01-31	Schering Corp.	<input type="checkbox"/>
10	9965897	WO	A1	1999-12-23	Chiron Corporation	<input type="checkbox"/>
11	0038675	WO		2000-07-06	Smithkline Beecham, PLC	<input type="checkbox"/>
12	9838171	WO		1998-09-03	Signal Pharmaceuticals Inc.	<input type="checkbox"/>
13	0174768	WO	A2	2001-10-11	Vertex Pharmaceuticals Incorporated	<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

## NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>
	1	Alonso, M. et al., "GSK-3 Inhibitors: Discoveries and Developments", Current Medicinal Chemistry, 11, 755-763 (2004).	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10722374
Filing Date	2003-11-25
First Named Inventor	David Bebbington
Art Unit	1624
Examiner Name	Venkataraman Balasubramanian
Attorney Docket Number	VP/00-130-08 CON US

2	Anonymous, "Vertex Inhibitors of Aurora-2, glycogen synthase kinase-3 and Src Kinase", Expert Opin. Ther. Patents, 14(3): 439-443 (2004).	<input type="checkbox"/>
3	Baig, G.U. et al., "Triazines and Related Products. Part 28' Conversion of 3-Aryl-1-(2-cyanophenyl) triazines into 3-Aryl-1-nazolo-4(3H)-ones with Formamide" J. Chem. Soc. Perkin Trans. 1, 3765-2766 (1984).	<input type="checkbox"/>
4	Bischoff, J.R., et al., "A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers", The EMBO Journal, 17(11): 3052-3065 (1998).	<input type="checkbox"/>
5	Bischoff, J.R., et al., "The Aurora/Iplp kinase family: regulators of chromosome segregation and cytokinesis", CELL BIOLOGY, 9, 454-459 (1999).	<input type="checkbox"/>
6	Brunswick, D.J. et al., "Cyclic Amidines. Part XXIII. Novel Isomerism of Disubstituted Triocycloquinazolines and Molecular Orientations in Carcinogenesis", J. Chem. SOC. (C), 2641-2647 (1970).	<input type="checkbox"/>
7	Wolff, M.E., "Burger's Medicinal Chemistry and Drug Discovery," 5th ed., Vol. 1: Principles and Practice, 975-977 (1995).	<input type="checkbox"/>
8	Cohen, P. et al., "The renaissance of GSK3," Nat. Rev. Mol. Biol., 2, 769-776 (2001).	<input type="checkbox"/>
9	Eldar-Finkelman, H. et al., "Challenges and opportunities with glycogen synthase kinase-3 inhibitors for insulin resistance and Type 2 diabetes treatment," Expert Opinion on Investigational Drugs, 12(9): 1511-1519 (2003).	<input type="checkbox"/>
10	Harrington, E.A. et al., "VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo," Nat. Med., 10(3): 262-267 (2004).	<input type="checkbox"/>
11	Heutink, P., "Untangling tau-related dementia", Hum. Mol. Genet., 9(6): 979-986 (2000).	<input type="checkbox"/>
12	Nigg, E.A., "Mitotic Kinases as Regulators of Cell Division and its Checkpoints," Nat. Rev. Mol. Cell Biol., 2: 21-32 (2001).	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10722374
Filing Date	2003-11-25
First Named Inventor	David Bebbington
Art Unit	1624
Examiner Name	Venkataraman Balasubramanian
Attorney Docket Number	VP/00-130-08 CON US

13	Traxler, P. et al., "Use of a Pharmacophore Model for the Design of EGF-R Tyrosine Kinase Inhibitors: 4-(Phenylamino)pyrazolo[3,4-d]pyrimidines," J. Med. Chem., 40, 3601-3616 (1997).	<input type="checkbox"/>
14	CAPLUS listing Accession No. 1994:292136, Nakajima, Y. et al., "Pyrazoles agncultural and horticultural bactericides," JP 06065237 (1994).	<input type="checkbox"/>
15	DATABASE CA "Online!" Chemical Abstract Service, Columbus, OH, US; Kelarev, V.I. et al., "Synthesis of amino derivatives of 1,3,5-triazine containing 1,3,4-thiadiazole fragments," Database Accession No. 1998:69514 XP002242653 abstract & IZVESTIYA VYSSHIKH UCHEBNKH ZAVEDENII, KHIMIYA I KHIMICHESKAYA TEKHNLOGIYA, 40(5): 27-32 (1997).	<input type="checkbox"/>
16	Chalmers, D.T. et al., "Corticotrophin-releasing factor receptors: from molecular biology to drug design," TIPS, 17, 769-776 (2001).	<input type="checkbox"/>
17	Kim et al., "GSK3, a master switch regulating cell-fate specification and tumorigenesis," Current Opinion in Genetics & Development, 10:508-514 (2000).	<input type="checkbox"/>
18	Lyrer, P., Schweiz. Med. Wochenschr., 124(45); 2005-2012 (1994).	<input type="checkbox"/>
19	Gershon, H. et al., "Pyrimidines. 7. A Study of the Chlorination of Pyrimidines with Phosphorus Oxychloride in the Presence of N,N-Dimethylaniline", J. Heterocyclic Chem., 21, 1161 (1984).	<input type="checkbox"/>
20	Banker, G.S. et al., "Modern Pharmaceutics", 451 & 596, 3rd ed., Marcel Dekker, New York (1996).	<input type="checkbox"/>
21	Lovestone, S. et al., "Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells", Curr. Biol., 4(12), 1077-86 (1994)	<input type="checkbox"/>
22	Ivashchenko A. V. et al., "Synthesis and Study of Heteroaromatic Ligands Containing a Pyrimidine Ring", Khim. Geterotsikl. Soedin., (12), 1673-7, (1980) (in English).	<input type="checkbox"/>
23	Brownlee, J. et al., "Tau phosphorylation in transgenic mice expressing glycogen synthase kinase-3beta transgenes", Neuroreport, 8(15), 3251-5 (1997).	<input type="checkbox"/>



**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10722374
Filing Date	2003-11-25
First Named Inventor	David Bebbington
Art Unit	1624
Examiner Name	Venkataraman Balasubramanian
Attorney Docket Number	VP/00-130-08 CON US

24	Biagi, G. et al., "Synthesis of 4,6 Disubstituted and 4,5,6-Trisubstituted 2-Phenyl-pyrimidines and Their Affinity Towards A1 Adenosine Receptors", Farmaco., 52(1), 61-65 (1997).	<input type="checkbox"/>
25	Ali, N.M. et al., "Palladium-Catalyzed Cross Coupling Reactions of Arylboronic Acids with Pi-Deficient Heteroaryl Chlorides" Tetrahedron, 48 (37), 8117-8126 (1992).	<input type="checkbox"/>
26	Zhang, Z. et al., "Destabilization of $\beta$ catenin by mutations in presenilin-1 potentiates neuronal apoptosis", Nature, 395, 698-702 (1998).	<input type="checkbox"/>
27	Takashima, K. et al., "Tau Protein Kinase I is Essential for Amyloid $\beta$ -Protein-Induced Neurotoxicity", PNAS 90, 7789-7793 (1993).	<input type="checkbox"/>
28	Pei, J. et al., "Distribution, Levels, and Activity of Glycogen Synthase Kinase-3 in the Alzheimer Disease Brain", J. Neuropathol. Exp., 56, 70-78 (1997).	<input type="checkbox"/>
29	IUPAC Compendium of Chemical Terminology on a definition of "aliphatic compounds" found from <a href="http://www.chemsoc.org/chembytes/goldbook/index.htm">http://www.chemsoc.org/chembytes/goldbook/index.htm</a> (last visited on November 18, 2007).	<input type="checkbox"/>
30	Glossary of Class Names of Organic Compounds and Reactive Intermediates Based on Structure found from <a href="http://www.chem.qmul.ac.uk/iupac/class/index.html">http://www.chem.qmul.ac.uk/iupac/class/index.html</a> (last visited on November 18, 2007).	<input type="checkbox"/>
31	Nomenclature found from <a href="http://www.cem.msu.edu/~reusch/VirtualText/nomen1.htm">http://www.cem.msu.edu/~reusch/VirtualText/nomen1.htm</a> (last visited on November 18, 2007).	<input type="checkbox"/>
32	Coghlan et al., "Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription", Chemistry & Biology, 7, 793-83 (2000).	<input type="checkbox"/>
33	Klein, et al., "A molecular mechanism for the effect of lithium on development", PNAS, 93: 8455-8459 (1996).	<input type="checkbox"/>
34	Cross et al., "The inhibition of glycogen synthase kinase-3 by insulin or insulin-like growth factor 1 in the rat skeletal muscle cell line L6 is blocked by wortmannin, but not by rapamycin: evidence that wortmannin blocks activation of the mitogen-activated protein kinase pathway in L6 cells between Ras and Raf", Biochem J., 303, 21-26 (1994).	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10722374
Filing Date	2003-11-25
First Named Inventor	David Bebbington
Art Unit	1624
Examiner Name	Venkataraman Balasubramanian
Attorney Docket Number	VP/00-130-08 CON US

35	Massillon et al., "Identification of the glycogenic compound 5-iodotubercidin as a general protein kinase inhibitor", Biochem J., 299, 123-128 (1994).	<input type="checkbox"/>
36	Fox T. et al., "A single amino acid substitution makes ERK2 susceptible to pyridinyl imidazole inhibitors of p38 MAP kinase", Protein Sci., 7: 2249-2255 (1998).	<input type="checkbox"/>
37	Takayanagi, H. et al., "Suppression of arthritic bone destruction by adenovirus-mediated csk gene transfer to synovocytes and osteoclasts", J. Clin. Invest., 104, 137-146 (1999).	<input type="checkbox"/>
38	Boschelli et al., "Small molecule inhibitors of Src family kinases", Drugs of the Future, 25(7): 717-736 (2000).	<input type="checkbox"/>
39	Talamonti, M.S. et al., "Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer", J Clin Invest., 91(1): 53-60 (1993).	<input type="checkbox"/>
40	Lutz, M.L. et al., "Overexpression and Activation of the Tyrosine Kinase Src in Human Pancreatic Carcinoma", Biochem. Biophys. Res. 243, 503-508 (1998).	<input type="checkbox"/>
41	Rosen, N. et al., "Analysis of pp60c-src Protein Kinase Activity in Human Tumor Cell Lines and Tissues", J.Biol. Chem., 261, 13754-13759 (1986).	<input type="checkbox"/>
42	Boien, J.B. et al., "Activation of pp60c-src protein kinase activity in human colon carcinoma", PNAS, 84, 2251-2255 (1987).	<input type="checkbox"/>
43	Masaki, T. et al., "pp60c-src Activation in Hepatocellular Carcinoma of Humans and LEC Rats", Hepatology, 27, 1257 (1998).	<input type="checkbox"/>
44	Biscardi, J.S. et al., "c-Src, Receptor Tyrosine Kinases, and Human Cancer", Adv. Cancer Res., 76, 61 (1999).	<input type="checkbox"/>
45	Lynch, S.A. et al., "Increased Expression of the src Proto-Oncogene in Hairy Cell Leukemia and a Subgroup of B-Cell Lymphomas", Leukemia, 7(9), 1416-1422 (1993).	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10722374
Filing Date	2003-11-25
First Named Inventor	David Bebbington
Art Unit	1624
Examiner Name	Venkataraman Balasubramanian
Attorney Docket Number	VP/00-130-08 CON US

46	Ife, R.J. et al., "Reversible Inhibitors of the Gastric (H <sup>+</sup> /K <sup>+</sup> )-ATPase, 5. Substituted 2,4-Diaminoquinazolines and Thienopyrimidines", J. Med. Chem., 38(14); 2763 – 2773 (1995).	<input type="checkbox"/>
47	Rueeger, H et al., "Design, synthesis and SAR of a series of 2-substituted 4-amino-quinazoline neuroptide Y Y5 receptor antagonists", Bioorg. Med. Chem. Lett., 10(11), 1175-1180 (2000).	<input type="checkbox"/>
48	Singhal, N. et al., "Synthesis and Antimalarial Activity of Some New Quinazoline Derivatives", Indian Chem. Soc., 61, 690-693 (1984).	<input type="checkbox"/>
49	Kim, Y.Z. et al., "Synthesis and Antimicrobial Activity of Novel [(3-Aminopyrimidiniumyl)thio]methyl Cephalosporins", J. Med. Chem., 37(22); 3828 - 3833 (1994).	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

**EXAMINER SIGNATURE**

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.